<DOC>
	<DOC>NCT00553865</DOC>
	<brief_summary>The purpose of this study is to determine the optimal dosage of the clinical trial which is evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets</brief_title>
	<detailed_description>Evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>1. Adult men and women (Age 1875 years) 2. Uncomplicated essential hypertension: Clinic sitting SiDBP between 90 and 109 mmHg after 2 week placebo runin period 1. Secondary hypertension 2. History and/or signs of cardiovascular complications (eg; myocardial infarction, unstable angina) 3. Pregnancy or lactation 4. Contraindications to the antihypertensive drugs to be used during the treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>